$0.17
0.00% yesterday
Nasdaq, Jun 12, 10:16 pm CET
ISIN
US38000Q1022
Symbol
GLYC
Sector
Industry

GlycoMimetics, Inc. Stock price

$0.17
-0.09 35.36% 1M
-0.08 32.71% 6M
-0.08 33.33% YTD
-0.10 36.88% 1Y
-2.83 94.47% 5Y
-7.60 97.86% 10Y
-8.84 98.16% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
+0.00 0.00%
ISIN
US38000Q1022
Symbol
GLYC
Sector
Industry

Key metrics

Market capitalization $10.71m
Enterprise Value $5.10m
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.17
Free Cash Flow (TTM) Free Cash Flow $-25.70m
Cash position $5.61m
Short interest 3.21%

Is GlycoMimetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

GlycoMimetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast GlycoMimetics, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast GlycoMimetics, Inc.:

Hold
100%

Financial data from GlycoMimetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
5% 5%
-
- Research and Development Expense 14 14
29% 29%
-
-32 -32
17% 17%
-
- Depreciation and Amortization 0.04 0.04
73% 73%
-
EBIT (Operating Income) EBIT -33 -33
17% 17%
-
Net Profit -38 -38
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about GlycoMimetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

GlycoMimetics, Inc. Stock News

Neutral
Business Wire
8 days ago
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Biopharma, Inc. (“Crescent”), along with all proposals related to the Merger. The proposals were voted upon at GlycoMimetics' special meeting in lieu of the annual meeting of stockholders held on June 5, 2025 (...
Neutral
GlobeNewsWire
15 days ago
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced that management is scheduled to present at the Jefferies Global Healthcare Conference in New York on Thursday, June 5, 2025, at 11:05 a.m.
Neutral
Business Wire
28 days ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics, Inc. (NasdaqGM: GLYC) and Crescent Biopharma, Inc. Pursuant to the terms of the agreement, shareholders of GlycoMimetics will own approximately 3.1% of the combined company. KSF is seeking to dete...
More GlycoMimetics, Inc. News

Company Profile

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Head office United States
CEO Harout Semerjian
Employees 4
Founded 2003
Website glycomimetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today